Alzheimer's

Syndicate content

Piramal sees $1.5 bn revenue from Alzheimer's drug

Apr 16, 2012 | |
ajaypiramal-ap.jpg.crop_display.jpg

Dugmaker Piramal Healthcare sees revenue potential of $1.5 billion from its new florbetaben molecule, a possible Alzheimer's treatment acquired by the company in a deal with Germany's Bayer AG.

No Articles Found

No Articles Found

No Articles Found

I want to begin with a little story that was told to me by a leading executive at Aptech. He was exercising in a gym with a lot of younger people.

Shekhar Kapur’s Bandit Queen didn’t make the cut. Neither did Shaji Karun’s Piravi, which bagged 31 international awards.

Horoscope